Nearly 2,000 Drug Manufacturing Plants Are Overdue for FDA Inspections After COVID Delays, AP Finds

U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19

U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19